Skip to main navigation Skip to search Skip to main content

Functional and Structural Studies on the Esperamicin Thioesterase and Progress toward Understanding Enediyne Core Biosynthesis

  • Erome D. Hankore
  • , Mitchell D. Miller
  • , Abigael J. Kosgei
  • , Weijun Xu
  • , Kemin Tan
  • , Michael Endres
  • , Minakshi Bhardwaj
  • , Grazyna Joachimiak
  • , Andrzej Joachimiak
  • , George N. Phillips
  • , Jon S. Thorson
  • , Steven G. Van Lanen

Research output: Contribution to journalArticlepeer-review

Abstract

Enediynes are among the most potent antitumor and antibacterial natural products. Studies on their biosynthetic pathways have identified a shared, linear polyene precursor generated from an iterative type I polyketide synthase (PKSE) as the source of the enediyne warhead. A key step is the release of this polyene from the PKSE by a discrete thioesterase (TE). Here, we used X-ray crystallography, site-directed mutagenesis, and heterologous coexpression of PKSEs and TEs to elucidate how enediyne TEs mediate the production of the polyene. We solved the structure of wild-type EspE7 from esperamicin producer Actinomodura verrucosospora. The substrate binding pocket was also defined upon serendipitous cocrystallization of an EspE7 mutant with a fatty acyl-CoA ligand. Structural data and in vitro activity assays with EspE7 mutants provide strong evidence that Glu68 in EspE7 and the analogous Glu residue in other enediyne TEs functions as a key catalytic residue, thus supporting a hydrolysis mechanism for enediyne TEs that aligns with that of Pseudomonas sp. 4-HB-CoA TE. Furthermore, combinations of 9- and 10-membered enediyne PKSEs and TEs produced 1,3,5,7,9,11,13-pentadecaheptaene (1) as the major product. Thus, the data further support previous conclusions that 1 serves as the sole precursor for the biosynthesis of all enediyne cores.

Original languageEnglish
Pages (from-to)2360-2371
Number of pages12
JournalJournal of Natural Products
Volume88
Issue number10
DOIs
StatePublished - Oct 24 2025

Bibliographical note

Publisher Copyright:
© 2025 The Authors. Published by American Chemical Society and American Society of Pharmacognosy

Funding

The results shown in this report are derived in part from work performed at the Structural Biology Center, which is funded by the U.S. Department of Energy, Office of Biological and Environmental Research. GM/CA@APS has been funded by the National Cancer Institute (ACB-12002) and the National Institute of General Medical Sciences (AGM-12006, P30GM138396). NIH Grant S10 OD012289 funded the Eiger 16M detector at GM/CA-XSD. This research used resources from the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract DE-AC02-06CH11357. The results shown in this report are derived in part from work performed at the Structural Biology Center, which is funded by the U.S. Department of Energy, Office of Biological and Environmental Research. GM/CA@APS has been funded by the National Cancer Institute (ACB-12002) and the National Institute of General Medical Sciences (AGM-12006, P30GM138396). NIH Grant S10 OD012289 funded the Eiger 16M detector at GM/CA-XSD. This research used resources from the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract DE-AC02-06CH11357. National Institutes of Health Grants U01GM098248 (to G.N.P.), R01GM115261 (J.S.T. and G.N.P.), and R01CA217255 (J.S.T., G.N.P., and S.G.V.L.); the Center of Biomedical Research Excellence (COBRE) in Pharmaceutical Research and Innovation Grant P20GM130456 (J.S.T. and S.G.V.L.); the National Science Foundation BioXFEL Science and Technology Center (Grant 1231306 (G.N.P.); and the Robert A. Welch Foundation Grant C-2118 (G.N.P). National Institutes of Health Grants U01GM098248 (to G.N.P.), R01GM115261 (J.S.T. and G.N.P.), and R01CA217255 (J.S.T., G.N.P., and S.G.V.L.); the Center of Biomedical Research Excellence (COBRE) in Pharmaceutical Research and Innovation Grant P20GM130456 (J.S.T. and S.G.V.L.); the National Science Foundation BioXFEL Science and Technology Center (Grant 1231306 (G.N.P.); and the Robert A. Welch Foundation Grant C-2118 (G.N.P).

FundersFunder number
U.S. Department of Energy, Office of Biological and Environmental Research
Biological and Environmental Research
Center of Biomedical Research Excellence
U.S. Department of Energy
Office of Science Programs
U.S. Department of Energy (DOE) Office of ScienceDE-AC02-06CH11357
Welch FoundationC-2118
National Institute of General Medical Sciences DP2GM119177 Sophie Dumont National Institute of General Medical SciencesAGM-12006, P30GM138396
BioXFEL Science and Technology Center1231306
National Institutes of Health (NIH)U01GM098248, R01CA217255, R01GM115261, S10 OD012289
Center of Biomedical Research Excellence (COBRE) in Pharmaceutical Research and InnovationP20GM130456
Argonne National LaboratoryDE-AC02-06CH11357
National Childhood Cancer Registry – National Cancer InstituteACB-12002
NIHS10 OD012289

    ASJC Scopus subject areas

    • Analytical Chemistry
    • Molecular Medicine
    • Pharmacology
    • Pharmaceutical Science
    • Drug Discovery
    • Complementary and alternative medicine
    • Organic Chemistry

    Fingerprint

    Dive into the research topics of 'Functional and Structural Studies on the Esperamicin Thioesterase and Progress toward Understanding Enediyne Core Biosynthesis'. Together they form a unique fingerprint.

    Cite this